Endogenous dynorphin in epileptogenesis and epilepsy: anticonvulsant net effect via kappa opioid receptors.

Neuropsychiatric disorders are one of the main challenges of human medicine with epilepsy being one of the most common serious disorders of the brain. Increasing evidence suggest neuropeptides, particularly the opioids, play an important role in epilepsy. However, little is known about the mechanisms of the endogenous opioid system in epileptogenesis and epilepsy. Therefore, we investigated the role of endogenous prodynorphin-derived peptides in epileptogenesis, acute seizure behaviour and epilepsy in prodynorphin-deficient mice. Compared with wild-type littermates, prodynorphin knockout mice displayed a significantly reduced seizure threshold as assessed by tail-vein infusion of the GABA(A) antagonist pentylenetetrazole. This phenotype could be entirely rescued by the kappa receptor-specific agonist U-50488, but not by the mu receptor-specific agonist DAMGO. The delta-specific agonist SNC80 decreased seizure threshold in both genotypes, wild-type and knockout. Pre-treatment with the kappa selective antagonist GNTI completely blocked the rescue effect of U-50488. Consistent with the reduced seizure threshold, prodynorphin knockout mice showed faster seizure onset and a prolonged time of seizure activity after intracisternal injection of kainic acid. Three weeks after local injection of kainic acid into the stratum radiatum CA1 of the dorsal hippocampus, prodynorphin knockout mice displayed an increased extent of granule cell layer dispersion and neuronal loss along the rostrocaudal axis of the ipsi- and partially also of the contralateral hippocampus. In the classical pentylenetetrazole kindling model, dynorphin-deficient mice showed significantly faster kindling progression with six out of eight animals displaying clonic seizures, while none of the nine wild-types exceeded rating 3 (forelimb clonus). Taken together, our data strongly support a critical role for dynorphin in the regulation of hippocampal excitability, indicating an anticonvulsant role of kappa opioid receptors, thereby providing a potential target for antiepileptic drugs.

[1]  Peng Xia,et al.  Regulation of the glutamate transporter EAAC1 by expression and activation of delta-opioid receptor. , 2006, European Journal of Neuroscience.

[2]  A. Basbaum,et al.  Decoy peptides that bind dynorphin noncovalently prevent NMDA receptor-mediated neurotoxicity. , 2006, Journal of proteome research.

[3]  F. Piva,et al.  Distribution of kappa opioid receptors in the brain of young and old male rats. , 1989, Life sciences.

[4]  Ivan Soltesz,et al.  Postsynaptic effects of GABAergic synaptic diversity: regulation of neuronal excitability by changes in IPSC variance , 2002, Neuropharmacology.

[5]  Peter Saggau,et al.  Mu-opioid receptors facilitate the propagation of excitatory activity in rat hippocampal area CA1 by disinhibition of all anatomical layers. , 2003, Journal of neurophysiology.

[6]  Peng Xia,et al.  Regulation of the glutamate transporter EAAC1 by expression and activation of δ‐opioid receptor , 2006 .

[7]  F. F. Weight,et al.  Dynorphin A inhibits NMDA receptors through a pH-dependent mechanism , 2003, Molecular and Cellular Neuroscience.

[8]  C. Drake,et al.  Mu opioid receptors are in discrete hippocampal interneuron subpopulations , 2002, Hippocampus.

[9]  F CONTAMIN,et al.  [Temporal lobe epilepsy]. , 1954, La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris.

[10]  C. Drake,et al.  Mu opioid receptors are in somatodendritic and axonal compartments of GABAergic neurons in rat hippocampal formation , 1999, Brain Research.

[11]  T. Watanabe,et al.  Opioid μ-deficient CXBK mouse and the role of μ 1-receptors in electrically induced convulsions , 1992, Brain Research.

[12]  A. Depaulis,et al.  Recurrent seizures and hippocampal sclerosis following intrahippocampal kainate injection in adult mice: electroencephalography, histopathology and synaptic reorganization similar to mesial temporal lobe epilepsy , 1999, Neuroscience.

[13]  A. Levine,et al.  The kappa-opioid antagonist GNTI reduces U50,488-, DAMGO-, and deprivation-induced feeding, but not butorphanol- and neuropeptide Y-induced feeding in rats , 2001, Brain Research.

[14]  H. Akil,et al.  κ1 Receptor mRNA Distribution in the Rat CNS: Comparison to κ Receptor Binding and Prodynorphin mRNA , 1994, Molecular and Cellular Neuroscience.

[15]  H. Mosberg,et al.  Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. , 1993, The Journal of pharmacology and experimental therapeutics.

[16]  C. Schwarzer,et al.  Distribution of prodynorphin mRNA and its interaction with the NPY system in the mouse brain , 2006, Neuropeptides.

[17]  J. Pintar,et al.  Localization of opioid receptor antagonist [3H]-LY255582 binding sites in mouse brain: Comparison with the distribution of mu, delta and kappa binding sites , 2005, Neuropeptides.

[18]  H. Akil,et al.  Kappa 1 receptor mRNA distribution in the rat CNS: comparison to kappa receptor binding and prodynorphin mRNA. , 1994, Molecular and cellular neurosciences.

[19]  C. Baumgartner,et al.  A functional polymorphism in the prodynorphin gene promotor is associated with temporal lobe epilepsy , 2002, Annals of neurology.

[20]  G. Sperk,et al.  Distribution of the major γ‐aminobutyric acidA receptor subunits in the basal ganglia and associated limbic brain areas of the adult rat , 2001, The Journal of comparative neurology.

[21]  K. Halasy,et al.  Kappa opioid receptor is expressed by somatostatin- and neuropeptide Y-containing interneurons in the rat hippocampus , 2002, Brain Research.

[22]  I. Kitchen,et al.  Region selective up-regulation of micro-, delta- and kappa-opioid receptors but not opioid receptor-like 1 receptors in the brains of enkephalin and dynorphin knockout mice. , 2003, Neuroscience.

[23]  P. Kwan,et al.  Early identification of refractory epilepsy. , 2000, The New England journal of medicine.

[24]  C. Polkey.  Clinical outcome of epilepsy surgery , 2004, Current opinion in neurology.

[25]  E. Stuenkel,et al.  κ-Opioid Receptor Activation Modulates Ca2+Currents and Secretion in Isolated Neuroendocrine Nerve Terminals , 1997, The Journal of Neuroscience.

[26]  G. Koob,et al.  Epilepsy, CNS viral injury and dynorphin. , 2004, Trends in pharmacological sciences.

[27]  P. Mediratta,et al.  Studies on the anticonvulsant effect of U50488H on maximal electroshock seizure in mice , 2003, Pharmacology Biochemistry and Behavior.

[28]  Hannah R Cock,et al.  Focal treatment for refractory epilepsy: hope for the future? , 2004, Brain Research Reviews.

[29]  F. Tortella,et al.  Endogenous opioid peptides and epilepsy: quieting the seizing brain? , 1988, Trends in pharmacological sciences.

[30]  J. McNamara.  Emerging insights into the genesis of epilepsy , 1999, Nature.

[31]  P. Portoghese,et al.  5'-Guanidinonaltrindole, a highly selective and potent κ-opioid receptor antagonist , 2000 .

[32]  R. Caudle,et al.  A novel interaction between dynorphin(1–13) and an N-methyl-d-aspartate site , 1988, Brain Research.

[33]  Josemir W Sander,et al.  The natural history of epilepsy: an epidemiological view , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[34]  S. Remy,et al.  Modulation of voltage-dependent sodium channels by the δ-agonist SNC80 in acutely isolated rat hippocampal neurons , 2004, Neuropharmacology.

[35]  G. Glaser,et al.  A Review of Mouse Mutants as Genetic Models of Epilepsy , 1985, Epilepsia.

[36]  D. Goldstein,et al.  Failure to replicate previously reported genetic associations with sporadic temporal lobe epilepsy: where to from here? , 2005, Brain : a journal of neurology.

[37]  M. Wollemann,et al.  Non-opioid actions of opioid peptides. , 2004, Life sciences.

[38]  S. Henriksen,et al.  Opioid peptides and epileptogenesis in the limbic system: cellular mechanisms. , 1986, Advances in neurology.

[39]  R. Nicoll,et al.  The opioid peptide dynorphin mediates heterosynaptic depression of hippocampal mossy fibre synapses and modulates long-term potentiation , 1993, Nature.

[40]  G. Siggins,et al.  Dynorphin selectively augments the M-current in hippocampal CA1 neurons by an opiate receptor mechanism. , 1999, Journal of neurophysiology.

[41]  G. Sperk,et al.  Neuropeptide Y and somatostatin immunoreactivity in the rat hippocampus after moderate hypoxia , 1996, Naunyn-Schmiedeberg's Archives of Pharmacology.

[42]  F. Bloom,et al.  OPIOID PEPTIDES IN THE HIPPOCAMPUS: ANATOMICAL AND PHYSIOLOGICAL CONSIDERATIONS * , 1982, Annals of the New York Academy of Sciences.

[43]  R. M. Jones,et al.  5'-Guanidinonaltrindole, a highly selective and potent kappa-opioid receptor antagonist. , 2000, European journal of pharmacology.

[44]  C. Chavkin,et al.  Dynorphin is a specific endogenous ligand of the kappa opioid receptor. , 1982, Science.

[45]  C. Chavkin,et al.  Endogenous dynorphins inhibit excitatory neurotransmission and block LTP induction in the hippocampus , 1993, Nature.

[46]  P. Schwartzkroin,et al.  Dynorphin opioids present in dentate granule cells may function as retrograde inhibitory neurotransmitters , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[47]  F. Tortella,et al.  Characterization of opioid peptide-like anticonvulsant activity in rat cerebrospinal fluid , 1988, Brain Research.

[48]  D. Thompson,et al.  Pulsed high-energy γ-rays from the radio pulsar PSR1706–44 , 1993, Nature.

[49]  G. Siggins,et al.  Voltage-dependent effects of opioid peptides on hippocampal CA3 pyramidal neurons in vitro , 1994, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[50]  Hantao Liu,et al.  Opioid peptide pharmacology and immunocytochemistry in an animal model of self-sustaining status epilepticus , 1999, Neuroscience.

[51]  H. Homayoun,et al.  The role of nitric oxide in the proconvulsant effect of δ-opioid agonist SNC80 in mice , 2002, Neuroscience Letters.

[52]  C. Drake,et al.  Opioid Modulation of Recurrent Excitation in the Hippocampal Dentate Gyrus , 2000, The Journal of Neuroscience.

[53]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[54]  V. Shukla,et al.  Nonopioid motor effects of dynorphin A and related peptides: structure dependence and role of the N-methyl-D-aspartate receptor. , 1997, The Journal of pharmacology and experimental therapeutics.

[55]  J. Froehlich.  Opioid Peptides , 1997, Alcohol health and research world.

[56]  G. Koob,et al.  Kappa opioid control of seizures produced by a virus in an animal model. , 2006, Brain : a journal of neurology.

[57]  G. Bell,et al.  Distribution of κ Opioid Receptor mRNA in Adult Mouse Brain: An in Situ Hybridization Histochemistry Study , 1994, Molecular and Cellular Neuroscience.

[58]  T. Kai,et al.  Developmental and Regional Alteration of κ-Opioid Receptors in Seizure-Susceptible EL Mouse Brain , 1998, Neurochemical Research.

[59]  C. Lupica,et al.  Opioid Inhibition of Hippocampal Interneurons via Modulation of Potassium and Hyperpolarization-Activated Cation (Ih) Currents , 1998, The Journal of Neuroscience.

[60]  S. Horvath,et al.  Prodynorphin gene promoter polymorphism and temporal lobe epilepsy , 2003, Annals of neurology.

[61]  I. Kitchen,et al.  Region selective up-regulation of μ-, δ- and κ-opioid receptors but not opioid receptor-like 1 receptors in the brains of enkephalin and dynorphin knockout mice , 2003, Neuroscience.